Atlas Therapeutics Corporation is a publicly-held Nevada corporation trading on the OTC Bulletin Board under the symbol ATTH.
Atlas is focused on preserving and growing the existing brand identity of MYO-T12® by refining its technical profile, and designing and implementing a marketing and sales strategy to increase penetration of the product into the existing health and fitness community. Management is also building a corporate infrastructure capable of achieving the company's broader goals
Currently Atlas operates two offices:
4640 Admiralty Way
Marina Del Rey, CA 90292
This office handles Finance, Marketing and Public Relations
The Hanover Technical Centre
45 Horsehill Road
Cedar Knolls NJ, 07927
Share StatisticsOutstanding: 66,013,997
(as of November 14, 2011)
Atlas Therapeutics Corporation
4640 Admiralty Way
Marina del Rey, CA 90292
Investor RelationsDavid Zazoff
Transfer AgentIsland Stock Transfer
100 Second Avenue South
St. Petersburg, FL 33701
Chief Executive Officer, President, Secretary, Treasurer and Director
J.B. Bernstein joined us as Chief Executive Officer, President, Secretary, Treasurer and Director in February 2011. Since 1994, he has been the co-founder and president of Pro Access, Inc., a boutique athlete representation firm, which has represented baseball and football legends such as Barry Bonds, Barry Sanders, Emmitt Smith and Curtis Martin. Since 2007, Mr. Bernstein has served as chief marketing officer of Seven Figures Management, a sports marketing and athlete representation firm. From 1990 to 1994, Mr. Bernstein served as director of business development for The Upper Deck Company. Mr. Bernstein received a bachelor's degree in political economics from the University of Massachusetts Amherst in 1986 and his master's degree from The London School of Economics in 1987. He received a Ph.D. in physics from the University of Southern California in 2006 and is currently pursuing a second Ph.D. a related field.
Carlon Colker, M.D., FACN
Chief Medical Officer, Executive Vice President
Carlon M. Colker, M.D., FACN joined us as Chief Medical Officer and Executive Vice President in February 2011. Since 1996, he has headed Peak Wellness, Inc, a an integrative medical healthcare provider focused on private, personal medical and healthcare coupled with nutrition, diet, and weight loss counseling, sports rehabilitation, physical therapy, and exercise physiology. His practice specialties include internal medicine, sports medicine, and sports nutrition. Dr. Colker is an attending physician at Beth Israel Medical Center in New York City and at Greenwich Hospital in Greenwich, Connecticut. As a special care physician, Dr. Colker has taken care of the most critically-ill patients in the intensive care unit at both St. Joseph Medical Center and Stamford Hospital in Connecticut. In addition to his practice, Dr. Colker is also one of the premier published researchers in the field of integrative care and a Fellow of the American College of Nutrition. He is widely regarded as one of the world's foremost experts on wellness, physical performance, athletic enhancement, and performance nutrition. Dr. Colker is an internationally recognized consultant on health and fitness and has worked with governments, large health systems, and private companies, as well as with numerous Olympic and professional athletes and celebrities. He was the lead researcher in the creation of various nutritional supplements including Metabolife's Metabolife 356, Twinlab's Ripped Fuel, Cytodyne's Xenadrine RFA-1 and Xenadrine-EFX. Dr. Colker has advised sports teams and athletes from around the globe and has appeared on such shows as ESPN's Outside the Lines, NBC's Health Segment, Court TV and ABC World News Tonight. Dr. Colker received his bachelor's degree from Manhattanville College in May 1988 and his M.D. from Sackler School of Medicine in May 1993.
Metabolife 356® is a Registered Trademark of Metabolife. Ripped Fuel ®is a Registered Trademark of Twin Lab. Xenadrine RFA-1® and Xenadrine-EFX® are Registered Trademarks of Cytodyne
Atlas Therapeutics intends to create and distribute a full line of revolutionary nutritional supplements designed to maximize the results for people who wish to live "High-Performance Lifestyles." Our approach will be to bring the highest standards of research science, testing, quality control, and regulation to our products and customers in order to build our reputation as the WHITE KNIGHT in the nutraceutical category.
MYO-T12®MYO-T12 has been engineered to modulate the bioactivity of a natural regulatory protein called myostatin.
Myostatin acts to inhibit muscle growth and recovery.
MYO-T12 is manufactured to optimize biological activity and has been CLINICALLY VALIDATED, demonstrating the product's potential to redefine existing standards of physical enhancement.
In clinical trials, MYO-T12 reduced the Myostatin levels of participants by an average of 46.4% within 12 hours of taking the first dose*. Myostatin levels of participants returned to their pre-use levels within 24 hours of ceasing product use. Because the therapeutic effect is reversible, users are able to derive the benefits without the side effects of permanent inhibition.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
FactsThe only clinically validated myostatin modulator on the market.
•In clinical trials, MYO-T12® reduced the myostatin levels of participants by an average of 46.4% within 12 hours of taking the first dose. Myostatin levels of participants returned to their pre-use levels within 24 hours of ceasing product use.
•Myostatin inhibition is associated with enhanced muscle growth and repair.
•Elevated levels of myostatin are known to negatively regulate skeletal muscle mass.
ATTH Research Report-